{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-091022","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.442548+00:00","generated_at":"2026-06-11T11:11:12.750676+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Jaguar Health Q2 net loss $12.2M, revenue $2.7M (+36% QoQ); OnTarget Phase 3 topline due late Oct","bullets":["Net loss attributable to shareholders $12.2M in Q2 2023 vs $9.4M in Q2 2022; diluted EPS ($0.42) vs ($0.12).","Combined net revenue for Mytesi and Canalevia-CA1 $2.7M, up 36% QoQ but down 8% YoY.","Loss from operations increased to $8.1M from $6.5M YoY; R&D spend rose to $4.3M from $2.5M.","Mytesi prescription volume up 4% sequentially; Canalevia-CA1 net revenue $39K (+40% QoQ).","Top line results from Phase 3 OnTarget trial of crofelemer for cancer therapy-related diarrhea expected late October 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-091022","json":"https://secwatch.observer/filing/0001104659-23-091022.json","markdown":"https://secwatch.observer/filing/0001104659-23-091022.md","text":"https://secwatch.observer/filing/0001104659-23-091022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923091022/0001104659-23-091022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923091022/tm2323630d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T11:11:12.750676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"11a243e707244f36edb5754760a0d7ed05abf68c","claim":"Jaguar Health, Inc. reported second quarter 2023 results: revenue approximately $2.7 million.","evidence_excerpt":"was approximately $2.7 million in the second quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923091022/0001104659-23-091022-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023"},{"label":"Revenue","value":"approximately $2.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}